Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

[Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism].

Duan H, Wang Y, Song D, Chen Z, Qiu J, Lu L, Jiang S, Liu S, Tan S.

Nan Fang Yi Ke Da Xue Xue Bao. 2013 Jun;33(6):826-31. Chinese.

2.

Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.

Andrianov AM, Kashyn IA, Tuzikov AV.

J Mol Graph Model. 2015 Sep;61:262-71. doi: 10.1016/j.jmgm.2015.08.003. Epub 2015 Aug 8.

PMID:
26298811
3.

Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.

Tintori C, Selvaraj M, Badia R, Clotet B, Esté JA, Botta M.

ChemMedChem. 2013 Mar;8(3):475-83. doi: 10.1002/cmdc.201200584. Epub 2013 Feb 12.

PMID:
23404750
5.

Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S.

J Biol Chem. 2005 Mar 25;280(12):11259-73. Epub 2005 Jan 7.

6.

3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.

Li M, Duan J, Qiu J, Yu F, Che X, Jiang S, Li L.

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1455-64. doi: 10.1089/AID.2013.0043. Epub 2013 Jun 18.

8.

Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.

Lai W, Huang L, Ho P, Li Z, Montefiori D, Chen CH.

Antimicrob Agents Chemother. 2008 Jan;52(1):128-36. Epub 2007 Oct 22.

9.

Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.

Hoorelbeke B, Huskens D, Férir G, François KO, Takahashi A, Van Laethem K, Schols D, Tanaka H, Balzarini J.

Antimicrob Agents Chemother. 2010 Aug;54(8):3287-301. doi: 10.1128/AAC.00254-10. Epub 2010 May 24.

11.

Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.

Férir G, Hänchen A, François KO, Hoorelbeke B, Huskens D, Dettner F, Süssmuth RD, Schols D.

Virology. 2012 Nov 25;433(2):308-19. doi: 10.1016/j.virol.2012.08.007. Epub 2012 Sep 7.

12.

Lignosulfonic acid exhibits broadly anti-HIV-1 activity--potential as a microbicide candidate for the prevention of HIV-1 sexual transmission.

Qiu M, Wang Q, Chu Y, Yuan Z, Song H, Chen Z, Wu Z.

PLoS One. 2012;7(4):e35906. doi: 10.1371/journal.pone.0035906. Epub 2012 Apr 27.

13.

Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK.

Virology. 2005 Sep 1;339(2):213-25.

14.

Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N.

Antimicrob Agents Chemother. 2013 May;57(5):2076-86. doi: 10.1128/AAC.02588-12. Epub 2013 Feb 12.

17.

Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.

Teixeira C, Gomes JR, Gomes P, Maurel F, Barbault F.

Eur J Med Chem. 2011 Apr;46(4):979-92. doi: 10.1016/j.ejmech.2011.01.046. Epub 2011 Feb 3. Review. Erratum in: Eur J Med Chem. 2011 Aug;46(8):3541. Barbault, Florent [added].

PMID:
21345545
18.

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.

J Virol. 1996 Feb;70(2):753-62.

19.

Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding.

Uttekar MM, Das T, Pawar RS, Bhandari B, Menon V, Nutan, Gupta SK, Bhat SV.

Eur J Med Chem. 2012 Oct;56:368-74. doi: 10.1016/j.ejmech.2012.07.030. Epub 2012 Jul 24.

PMID:
22858223
20.

Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.

Kramer VG, Varsaneux O, Oliviera M, Colby-Germinario SP, Mesplède T, Wainberg MA.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):7-14. doi: 10.1097/QAI.0000000000000223.

PMID:
24872133

Supplemental Content

Support Center